Loading…

Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?

Stage iii lung cancer is the most advanced stage of lung cancer for which the potential of curative treatment is often discussed. However, a large proportion of patients are treated with palliative intent. An understanding of the time-dependent and -independent factors contributing to the choice of...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2015-12, Vol.22 (6), p.399-404
Main Authors: Robinson, A G, Young, K, Balchin, K, Owen, T, Ashworth, A
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c378t-b5669490ca5bb563a64766f850047380d7dbb905fe3e18822d47365f373e4bc3
cites
container_end_page 404
container_issue 6
container_start_page 399
container_title Current oncology (Toronto)
container_volume 22
creator Robinson, A G
Young, K
Balchin, K
Owen, T
Ashworth, A
description Stage iii lung cancer is the most advanced stage of lung cancer for which the potential of curative treatment is often discussed. However, a large proportion of patients are treated with palliative intent. An understanding of the time-dependent and -independent factors contributing to the choice of palliative-intent treatment is needed to help optimize patient outcomes. This retrospective cohort study of patients with stage iii non-small-cell lung cancer (nsclc) newly diagnosed between 1 January 2008 and 31 December 2012 at the Cancer Centre of Southeastern Ontario collected data including patient demographics, clinical characteristics, tumour characteristics, treatment, and outcomes. Of 237 patients with stage iii nsclc included in the study, 130 were not treated with radical or curative intent (55%). Major time-independent variables cited for palliative-intent treatment included extreme age (5%), comorbidity (27%), patient choice (5%), and poor lung function (5%). Time-dependent variables included tumour progression on imaging (15%), weight loss (33%), performance status (32%), and the occurrence of a major complication such as hemoptysis, lung collapse, or pulmonary embolism (7%). A significant number of patients (20%) experienced a decline in performance status-to 2, 3, or 4 from 0 or 1-over the course of the diagnostic journey, and 12% experienced a transition from no weight loss to more than 10% weight loss. A significant proportion of patients receive palliative therapy for stage iii nsclc because of changes that occur during the diagnostic journey. Shortening or altering that pathway to avoid tumour growth or patient deterioration during care could allow for more patients to be treated with curative intent.
doi_str_mv 10.3747/co.22.2689
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4687660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1752787285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-b5669490ca5bb563a64766f850047380d7dbb905fe3e18822d47365f373e4bc3</originalsourceid><addsrcrecordid>eNpVkd2KFDEQhYMo7o_e-ABSlyL0mE46P-2FIsuqAwuC7H1Ip6tnIt3JmKRX9ll8WTO766JXVVR9nFPUIeRVSzdcdeqdixvGNkzq_gk5bVWrG6VY_7T2ba8bSgU7IWc5_6CUc6XUc3LCpGqFVuyU_P6ONseQYYoJDnaevS3-BqEktGXBUDL4ALnYHcJ2u4UQQ5OXyjUO5xnmNezA2eAwvYdfe1vAxVCSH9biYwCfYbEjwnALxS_YjHjAMFZVcHsbdngnXtYlrgnu_Is_LqtdWfPHF-TZZOeMLx_qObn-fHl98bW5-vZle_HpqnFc6dIMQsq-66mzYqg9t7JTUk5aUNoprumoxmHoqZiQY6s1Y2MdSzFxxbEbHD8nH-5lD-uw4OjqBcnO5pD8YtOtidab_zfB780u3phO6mpEq8CbB4EUf66Yi1l8Pr7HBoxrNq0STNVva1HRt_eoSzHnhNOjTUvNMUzjomHMHMOs8Ot_D3tE_6bH_wBtep3q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1752787285</pqid></control><display><type>article</type><title>Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?</title><source>PubMed (Medline)</source><creator>Robinson, A G ; Young, K ; Balchin, K ; Owen, T ; Ashworth, A</creator><creatorcontrib>Robinson, A G ; Young, K ; Balchin, K ; Owen, T ; Ashworth, A</creatorcontrib><description>Stage iii lung cancer is the most advanced stage of lung cancer for which the potential of curative treatment is often discussed. However, a large proportion of patients are treated with palliative intent. An understanding of the time-dependent and -independent factors contributing to the choice of palliative-intent treatment is needed to help optimize patient outcomes. This retrospective cohort study of patients with stage iii non-small-cell lung cancer (nsclc) newly diagnosed between 1 January 2008 and 31 December 2012 at the Cancer Centre of Southeastern Ontario collected data including patient demographics, clinical characteristics, tumour characteristics, treatment, and outcomes. Of 237 patients with stage iii nsclc included in the study, 130 were not treated with radical or curative intent (55%). Major time-independent variables cited for palliative-intent treatment included extreme age (5%), comorbidity (27%), patient choice (5%), and poor lung function (5%). Time-dependent variables included tumour progression on imaging (15%), weight loss (33%), performance status (32%), and the occurrence of a major complication such as hemoptysis, lung collapse, or pulmonary embolism (7%). A significant number of patients (20%) experienced a decline in performance status-to 2, 3, or 4 from 0 or 1-over the course of the diagnostic journey, and 12% experienced a transition from no weight loss to more than 10% weight loss. A significant proportion of patients receive palliative therapy for stage iii nsclc because of changes that occur during the diagnostic journey. Shortening or altering that pathway to avoid tumour growth or patient deterioration during care could allow for more patients to be treated with curative intent.</description><identifier>ISSN: 1198-0052</identifier><identifier>ISSN: 1718-7729</identifier><identifier>EISSN: 1718-7729</identifier><identifier>DOI: 10.3747/co.22.2689</identifier><identifier>PMID: 26715872</identifier><language>eng</language><publisher>Canada: Multimed Inc</publisher><subject>Original</subject><ispartof>Current oncology (Toronto), 2015-12, Vol.22 (6), p.399-404</ispartof><rights>2015 Multimed Inc. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-b5669490ca5bb563a64766f850047380d7dbb905fe3e18822d47365f373e4bc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687660/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687660/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26715872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robinson, A G</creatorcontrib><creatorcontrib>Young, K</creatorcontrib><creatorcontrib>Balchin, K</creatorcontrib><creatorcontrib>Owen, T</creatorcontrib><creatorcontrib>Ashworth, A</creatorcontrib><title>Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?</title><title>Current oncology (Toronto)</title><addtitle>Curr Oncol</addtitle><description>Stage iii lung cancer is the most advanced stage of lung cancer for which the potential of curative treatment is often discussed. However, a large proportion of patients are treated with palliative intent. An understanding of the time-dependent and -independent factors contributing to the choice of palliative-intent treatment is needed to help optimize patient outcomes. This retrospective cohort study of patients with stage iii non-small-cell lung cancer (nsclc) newly diagnosed between 1 January 2008 and 31 December 2012 at the Cancer Centre of Southeastern Ontario collected data including patient demographics, clinical characteristics, tumour characteristics, treatment, and outcomes. Of 237 patients with stage iii nsclc included in the study, 130 were not treated with radical or curative intent (55%). Major time-independent variables cited for palliative-intent treatment included extreme age (5%), comorbidity (27%), patient choice (5%), and poor lung function (5%). Time-dependent variables included tumour progression on imaging (15%), weight loss (33%), performance status (32%), and the occurrence of a major complication such as hemoptysis, lung collapse, or pulmonary embolism (7%). A significant number of patients (20%) experienced a decline in performance status-to 2, 3, or 4 from 0 or 1-over the course of the diagnostic journey, and 12% experienced a transition from no weight loss to more than 10% weight loss. A significant proportion of patients receive palliative therapy for stage iii nsclc because of changes that occur during the diagnostic journey. Shortening or altering that pathway to avoid tumour growth or patient deterioration during care could allow for more patients to be treated with curative intent.</description><subject>Original</subject><issn>1198-0052</issn><issn>1718-7729</issn><issn>1718-7729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkd2KFDEQhYMo7o_e-ABSlyL0mE46P-2FIsuqAwuC7H1Ip6tnIt3JmKRX9ll8WTO766JXVVR9nFPUIeRVSzdcdeqdixvGNkzq_gk5bVWrG6VY_7T2ba8bSgU7IWc5_6CUc6XUc3LCpGqFVuyU_P6ONseQYYoJDnaevS3-BqEktGXBUDL4ALnYHcJ2u4UQQ5OXyjUO5xnmNezA2eAwvYdfe1vAxVCSH9biYwCfYbEjwnALxS_YjHjAMFZVcHsbdngnXtYlrgnu_Is_LqtdWfPHF-TZZOeMLx_qObn-fHl98bW5-vZle_HpqnFc6dIMQsq-66mzYqg9t7JTUk5aUNoprumoxmHoqZiQY6s1Y2MdSzFxxbEbHD8nH-5lD-uw4OjqBcnO5pD8YtOtidab_zfB780u3phO6mpEq8CbB4EUf66Yi1l8Pr7HBoxrNq0STNVva1HRt_eoSzHnhNOjTUvNMUzjomHMHMOs8Ot_D3tE_6bH_wBtep3q</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Robinson, A G</creator><creator>Young, K</creator><creator>Balchin, K</creator><creator>Owen, T</creator><creator>Ashworth, A</creator><general>Multimed Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201512</creationdate><title>Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?</title><author>Robinson, A G ; Young, K ; Balchin, K ; Owen, T ; Ashworth, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-b5669490ca5bb563a64766f850047380d7dbb905fe3e18822d47365f373e4bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robinson, A G</creatorcontrib><creatorcontrib>Young, K</creatorcontrib><creatorcontrib>Balchin, K</creatorcontrib><creatorcontrib>Owen, T</creatorcontrib><creatorcontrib>Ashworth, A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current oncology (Toronto)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robinson, A G</au><au>Young, K</au><au>Balchin, K</au><au>Owen, T</au><au>Ashworth, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?</atitle><jtitle>Current oncology (Toronto)</jtitle><addtitle>Curr Oncol</addtitle><date>2015-12</date><risdate>2015</risdate><volume>22</volume><issue>6</issue><spage>399</spage><epage>404</epage><pages>399-404</pages><issn>1198-0052</issn><issn>1718-7729</issn><eissn>1718-7729</eissn><abstract>Stage iii lung cancer is the most advanced stage of lung cancer for which the potential of curative treatment is often discussed. However, a large proportion of patients are treated with palliative intent. An understanding of the time-dependent and -independent factors contributing to the choice of palliative-intent treatment is needed to help optimize patient outcomes. This retrospective cohort study of patients with stage iii non-small-cell lung cancer (nsclc) newly diagnosed between 1 January 2008 and 31 December 2012 at the Cancer Centre of Southeastern Ontario collected data including patient demographics, clinical characteristics, tumour characteristics, treatment, and outcomes. Of 237 patients with stage iii nsclc included in the study, 130 were not treated with radical or curative intent (55%). Major time-independent variables cited for palliative-intent treatment included extreme age (5%), comorbidity (27%), patient choice (5%), and poor lung function (5%). Time-dependent variables included tumour progression on imaging (15%), weight loss (33%), performance status (32%), and the occurrence of a major complication such as hemoptysis, lung collapse, or pulmonary embolism (7%). A significant number of patients (20%) experienced a decline in performance status-to 2, 3, or 4 from 0 or 1-over the course of the diagnostic journey, and 12% experienced a transition from no weight loss to more than 10% weight loss. A significant proportion of patients receive palliative therapy for stage iii nsclc because of changes that occur during the diagnostic journey. Shortening or altering that pathway to avoid tumour growth or patient deterioration during care could allow for more patients to be treated with curative intent.</abstract><cop>Canada</cop><pub>Multimed Inc</pub><pmid>26715872</pmid><doi>10.3747/co.22.2689</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1198-0052
ispartof Current oncology (Toronto), 2015-12, Vol.22 (6), p.399-404
issn 1198-0052
1718-7729
1718-7729
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4687660
source PubMed (Medline)
subjects Original
title Reasons for palliative treatments in stage III non-small-cell lung cancer: what contribution is made by time-dependent changes in tumour or patient status?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A00%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reasons%20for%20palliative%20treatments%20in%20stage%20III%20non-small-cell%20lung%20cancer:%20what%20contribution%20is%20made%20by%20time-dependent%20changes%20in%20tumour%20or%20patient%20status?&rft.jtitle=Current%20oncology%20(Toronto)&rft.au=Robinson,%20A%20G&rft.date=2015-12&rft.volume=22&rft.issue=6&rft.spage=399&rft.epage=404&rft.pages=399-404&rft.issn=1198-0052&rft.eissn=1718-7729&rft_id=info:doi/10.3747/co.22.2689&rft_dat=%3Cproquest_pubme%3E1752787285%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c378t-b5669490ca5bb563a64766f850047380d7dbb905fe3e18822d47365f373e4bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1752787285&rft_id=info:pmid/26715872&rfr_iscdi=true